RxSight, Inc.

For the period ended Dec 31, 2025. Filed Feb 25, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Feb 25, 2026

RXST$4.90+0.8%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations and Comprehensive Loss

(In thousands, except share and per share amounts)

	Year Ended December 31,
	2025	2024	2023
Sales	$134,479	$139,927	$89,077
Cost of sales	31,470	40,984	35,312
Gross profit	103,009	98,943	53,765
Operating expenses:
Selling, general and administrative	112,651	101,434	74,799
Research and development	38,549	34,367	29,051
Total operating expenses	151,200	135,801	103,850
Loss from operations	(48,191)	(36,858)	(50,085)
Other income (expense), net:
Interest expense	(19)	(21)	(3,308)
Interest and other income	9,332	9,474	6,574
Loss on extinguishment of term loan	—	—	(1,769)
Loss before income taxes	(38,878)	(27,405)	(48,588)
Income tax expense	66	50	20
Net loss	$(38,944)	$(27,455)	$(48,608)
Other comprehensive (loss) income
Unrealized (loss) gain on short-term investments	(136)	180	83
Foreign currency translation gain (loss)	23	(9)	7
Total other comprehensive (loss) income	(113)	171	90
Comprehensive loss	$(39,057)	$(27,284)	$(48,518)
Net loss per share:
Basic and diluted	$(0.95)	$(0.71)	$(1.41)
Weighted-average shares used in computing net loss per share:
Attributable to common stock, basic and diluted	40,850,739	38,867,726	34,455,111

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.